

Publications on side-effects induced by checkpoint inhibitors

Original articles in peer-reviewed journals:

1. **Heinzerling L**, De Toni EN, Schett G, Hundorfean G, Zimmer L (2019) Checkpoint-Inhibitoren: Diagnostik und Therapie von Nebenwirkungen. *Deutsches Ärzteblatt*, 116:119-26. DOI: 10.3238
2. Toussaint F, Hammon M, Erdmann M, Moreira A, Kirchberger MC, Schuler G, Schett G, **Heinzerling L** (2019) Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response. *Rheumatology*, May 5. <https://doi.org/10.1093/rheumatology/kez164>
3. **Heinzerling L**, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A (2019) Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. *Eur J Cancer*, 112:29-31. DOI: 10.1016/j.ejca.2019.01.015
4. Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mittel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, **Heinzerling L** (2018) Myositis and neuromuscular side effects induced by immune checkpoint inhibitors. *Eur J Cancer*, 106:12-23. DOI: 10.1016/j.ejca.2018.09.033
5. Knauss S, Ginesta Roque L, Hühnchen P, **Heinzerling L**, Böhmerle W, Endres M (2018) Neurological side effects of checkpoint inhibitors. *Nervenarzt*, Aug 2. <https://doi.org/10.1007/s00115-018-0571-8>
6. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, **Heinzerling L**, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG (2018) Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. *J Am Coll Cardiol*, 71(16):1755-64. DOI: 10.1016/j.jacc.2018.02.037
7. Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L (2018) Live-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy. *J Immunother*, 41(1):35-8. DOI: 10.1097/CJI.0000000000000190
8. Hassel JC*, **Heinzerling L***, Aberlec J, Bährd O, Eigentler TK, Grimm MO, Victor Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. *Cancer Treatment Rev*, 57:36-49. ISSN: 1532-1967 <https://doi.org/10.1016/j.ctrv.2017.05.003> * shared first authorship
9. Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, **Heinzerling L**, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. *Eur J Cancer*, 75:24-32. DOI: 10.1016/j.ejca.2016.12.038
10. **Heinzerling L**, Goldinger SM (2017) A review of serious adverse effects

under treatment with checkpoint inhibitors. *Curr Opin Oncol*, 29:136-44.
DOI: 10.1097/CCO.0000000000000358

11. **Heinzerling L**, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. *J Immunother Cancer*, 4:50. DOI: 10.1186/s40425-016-0152-y
12. Lankes K, Hundorfean G, Harrer T, Pommer AJ, Agaimy A, Angelovska I, Tajmir-Riahi A, Göhl J, Schuler G, Neurath MF, Hohenberger W, **Heinzerling L** (2016) Anti TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. *Oncoimmunology*, 5(6):e1128611. DOI: 10.1080/2162402X.2015.1128611
13. Kähler KC, Hassel JC, **Heinzerling L**, Loquai C, Mössner R, Ugurel S, Zimmer L, Gutzmer R (2016) Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. *JDDG*, 14(7):662-81. DOI: 10.1111/ddg.13047
14. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, **Heinzerling LM** (2016) Cutaneous, gastrointestinal, hepatic, endocrine and renal side effects of anti-PD-1 therapy. *Eur J Cancer*, 60:190-209. <https://doi.org/10.1016/j.ejca.2016.02.025>
15. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, **Heinzerling LM** (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side effects of anti-PD-1 therapy. *Eur J Cancer*, 60:210-25. <https://doi.org/10.1016/j.ejca.2016.02.024>
16. Uslu U, Hundorfean G, Harrer T, Schuler G, Heinzerling L (2015) Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. *J Immunother*, 38(5):212-5. DOI: 10.1097/CJI.0000000000000081
17. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Carola Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Pätzold S, Satzger I, Schadendorf D, Marc Schlaeppi M, Gerold Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Reinhard Dummer R, **Heinzerling LM** (2013) The price of tumor control: An analysis of rare side effects of anti CTLA-4 therapy in metastatic melanoma from the ipilimumab network. *PLOS ONE*, 8(1):e53745. DOI: 10.1371/journal.pone.0053745

18. Voskens CJ, Cavallaro A, Erdmann M, Dippel O1, Kaempgen E, Schuler G, Schuler-Thurner B, **Heinzerling L** (2012) Anti-CTLA-4 Induced Regression Of Spinal Cord Metastases In Association With Renal Failure, Atypical Pneumonia, Vision Loss And Hearing Loss. *J Clin Oncol*, 30(33):e356-7. DOI: 10.1200/JCO.2011.41.4359
19. Hundorfean G, Atreya R, Agaimy A, **Heinzerling L**, Kämpgen E, Schuler G, Neurath MF (2012) Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis. *Endoscopy*, 44 Suppl 2 UCTN:E78-9. DOI: 10.1055/s-0031-1291603

Books:

Medikamentöse Tumortherapie in der Dermato-Onkologie. **Heinzerling L**, Hartmann A, Hund M, Schuler G. Springer Verlag, 2014 (2. Auflage).